Epiglottitis medical therapy

Revision as of 00:45, 21 May 2014 by GeraldChi (talk | contribs)
Jump to navigation Jump to search

Epiglottitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Epiglottitis from other Diseases

Epidemiology and Demographics

Screening

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Rays

ECG

CT scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Epiglottitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Epiglottitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Epiglottitis medical therapy

CDC on Epiglottitis medical therapy

Epiglottitis medical therapy in the news

Blogs on Epiglottitis medical therapy

Directions to Hospitals Treating Epiglottitis

Risk calculators and risk factors for Epiglottitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alonso Alvarado, M.D. [2]

Overview

Epiglottitis is a medical emergency and warrants immediate establishment of a patent airway. Once the airway has been secured, cultures of blood and epiglottic surface should be obtained before administration of antibiotics. Appropriate antibiotic regimens with coverage of Streptococcus pneumoniae, beta-hemolytic streptococci, and Staphylococcus aureus include parenteral cefotaxime or ceftriaxone in combination with vancomycin (or levofloxacin in combination with clindamycin for penicillin-allergic patients). The use of racemic epinephrine or systemic corticosteroids does not shorten hospital stay nor reduce the need of artificial airway and is not recommended in routine practice.[1] Postexposure prophylaxis with rifampin should be given to selected household contacts when a Haemophilus influenzae epiglottitis is diagnosed.

Medical Therapy

Patients should receive empiric antibiotic treatment after sample for throat culture has been taken. The recomended treatment is a combination of a third generation cephaplosporin such as ceftriaxone or cefotaxime with an antistaphylococcal agent, active against.[2] If MRSA is not considered as a possible cause for the infection, ceftriaxone, cefotaxime or amplicilin/sulbactam IV monotherapy could be cosidered.[2]

Empiric Therapy[2]

Pediatric patient
Preferred Regimen
Vancomycin 10 mg/kg per dose IV q4h
PLUS
Ceftriaxone 50-75 mg/kg administered IV q24h
OR
Cefotaxime 50 mg/kg IV q8h
Alternative Regimen (If Allergic to Penicillin)
Clindamycin 7.5 mg/kg mg IV q6h
PLUS
Levofloxacin 100 mg/kg IV q24h
Adult patient
Preferred Regimen
Vancomycin 1 g IV q12h
PLUS
Ceftriaxone 2 g IV q24h
OR
Cefotaxime 2 g IV q8h
Alternative Regimen (If Allergic to Penicillin)
Clindamycin 600-900 mg IV q6h
PLUS
Levofloxacin 750 mg IV q24h

Pathogen based theerapy

▸ Click on the following categories to expand treatment regimens.


Bacteria

  ▸  Streptococcus pneumoniae

  ▸  Streptococcus sp

  ▸  Staphylococcus aureus

  ▸  Haemophilus influenzae

  ▸  Klebsiella pneumoniae

  ▸  Moraxella catarrhalis

  ▸  Neisseria sp

  ▸  Pasteurella multocida

  ▸  Pseudomonas sp

Fungi

  ▸  Candida albicans

  ▸  Aspergillus sp

Streptococcus pneumoniae
Preferred Regimen (sussceptible to penicillin)
Penicillin G 2 million units IV q4h
OR
Ceftriaxone 2 g IV q24h
OR
Clindamycin 600 mg IV q6h
Alternative Regimen (penicillin resistant strains)
Moxifloxacin 400 mg IV q24h
OR
Levofloxacin 750 mg IV q24h
OR
Vancomycin 1 g IV q12h
OR
Linezolid 600 mg IV q12h
OR
Ceftaroline 600 mg IV q12h
Streptococcus pyogenes
Preferred Regimen (sussceptible to penicillin)
Penicillin G 2 million units IV q4h
OR
Ceftriaxone 2 g IV q24h
OR
Clindamycin 600 mg IV q6h
Alternative Regimen (penicillin resistant strains)
Moxifloxacin 400 mg IV q24h
OR
Levofloxacin 750 mg IV q24h
OR
Vancomycin 1 g IV q12h
OR
Linezolid 600 mg IV q12h
OR
Ceftaroline 600 mg IV q12h
Streptococcus agalactiae
Preferred Regimen (sussceptible to penicillin)
Penicillin G 2 million units IV q4h
OR
Ceftriaxone 2 g IV q24h
OR
Clindamycin 600 mg IV q6h
Alternative Regimen (penicillin resistant strains)
Moxifloxacin 400 mg IV q24h
OR
Levofloxacin 750 mg IV q24h
OR
Vancomycin 1 g IV q12h
OR
Linezolid 600 mg IV q12h
OR
Ceftaroline 600 mg IV q12h|}
Streptococcus group C
Preferred Regimen (sussceptible to penicillin)
Penicillin G 2 million units IV q4h
OR
Ceftriaxone 2 g IV q24h
OR
Clindamycin 600 mg IV q6h
Alternative Regimen (penicillin resistant strains)
Moxifloxacin 400 mg IV q24h
OR
Levofloxacin 750 mg IV q24h
OR
Vancomycin 1 g IV q12h
OR
Linezolid 600 mg IV q12h
OR
Ceftaroline 600 mg IV q12h
Streptococcus angiosus
Preferred Regimen (sussceptible to penicillin)
Penicillin G 2 million units IV q4h
OR
Ceftriaxone 2 g IV q24h
OR
Clindamycin 600 mg IV q6h
Alternative Regimen (penicillin resistant strains)
Moxifloxacin 400 mg IV q24h
OR
Levofloxacin 750 mg IV q24h
OR
Vancomycin 1 g IV q12h
OR
Linezolid 600 mg IV q12h
OR
Ceftaroline 600 mg IV q12h|}
Meticillin susceptible Staphylococcus aureus
Preferred Regimen
Nafcillin 2 g IV q4-6h
OR
Oxacillin 2 mg IV q4-6h
OR
Cefazolin 2 g IV q8h
OR
Vancomycin 15 mg/kg IV q8h
Alternative Regimen
Dicloxacillin 500 mg PO q6h
OR
Cephalexin 500 mg PO q6h
OR
Clindamycin 300 mg PO q6h
OR
Clindamycin 300 mg PO q8h
OR
TMP/SMZ 160/800 mg PO q12h
Meticilling resistant Staphylococcus aureus
Preferred Regimen
Vancomycin 15-20 mg/kg IV q8-12h
OR
Daptomycin 4-6 mg/kg IV q24h
OR
Linezolid 600 mg IV q12h
Alternative Regimen (Vancomycin intermmediate sussceptibility)
Linezolid 600 mg/kg IV q12h
OR
Daptomycin 4-6 mg/kg IV q24h
OR
Ceftraoline 600 mg IV q8h
Alternative Regimen (Vancomycin resistance)
Teicoplanin 6 mg/kg IV q12h (total of three doses), 6 mg/kg IV q24h
OR
Telavancin 10 mg/kg q24h (1 hour infusion)
OR
Linezolid 600 mg/kg IV q12h
OR
Daptomycin 4-6 mg/kg IV q24h
Haemophilus influenzae
Preferred Regimen
Ceftriaxone 2 g IV q12h
OR
Cefotaxime 2 g IV q8h
Alternative Regimen
Levofloxacin 750 mg IV q24h
OR
Moxifloxacin 400 mg IV q8h
Klebsiella pneumoniae
Preferred Regimen
Ceftriaxone 2 g IV q12h
OR
Cefotaxime 2 g IV q8h
OR
Levofloxacin 750 mg IV q24h
Alternative Regimen
Imipenem 500 mg IV q6h
OR
Meropenem 1 g IV q8h
OR
Ertapenem 1 g IV q24h
Moraxella catrrhalis
Preferred Regimen
Amoxicillin-clavulanic acid 850/125 mg PO q24h
Alternative Regimen
Azithromycin 500 mg PO q24h one day, then 250 mg PO q24h
OR
TMP/SMZ 5 mg/kg IV q6—12h (TMP component)
Neisseria meningitidis
Preferred Regimen
Ceftriaxone 2 g IV q12h
OR
Cefotaxime 2 g IV q6h
Alternative Regimen
Penicillin G 4 million units IV q4h
OR
Chloramphenicol 100 mg/kg/day q6h, not exceed 4 g
Neisseria gonorrhoeae
Preferred Regimen
Ceftriaxone 250 mg IM single dose
Alternative Regimen
Azithromycin 2 g PO single dose
Pasteurella maltocida
Preferred Regimen
Penicillin VK 500 mg PO q12h
OR
Amoxicillin 500 mg PO q8h
OR
Amoxicillin-clavulanic acid 850/125 mg PO q12h
Alternative Regimen
Cefuroxime 500 mg PO q12h
OR
Levofloxacin 750 mg PO q24h
OR
Moxifloxacin 400 mg PO q24h
OR
Doxycycline 100 mg PO q12h
OR
Amoxicillin-clavulanic acid 850/125 mg PO q12h
Pseudomona sp
Preferred Regimen
Ceftazidime 2 g IV q8h
OR
Cefepime 2 g IV q8h
PLUS
Levofloxacin 750 mg IV q24h
OR
Moxifloxacin 400 mg PO q24h
Alternative Regimen (combination of)
Pseudomona sp
Preferred Regimen
Fluconzole 200 mg IV q24h for 14 days
OR
Fluconzole 200 mg PO q24h for 14 days
PLUS
Nystatin oral suspension PO q6h for 14 days
Alternative Regimen (combination of)
Itraconazole solution 200 mg PO q24h for 14 days
OR
Amphotericin B 0.3 mg/kg PO q12h 3 days, then q24h for 14 days
OR
Caspofungin PO q6h for 14 days


References

  1. Frantz TD, Rasgon BM, Quesenberry CP (1994). "Acute epiglottitis in adults. Analysis of 129 cases". JAMA. 272 (17): 1358–60. PMID 7933397.
  2. 2.0 2.1 2.2 Zoorob R, Sidani MA, Fremont RD, Kihlberg C (2012). "Antibiotic use in acute upper respiratory tract infections". Am Fam Physician. 86 (9): 817–22. PMID 23113461.